Casey C. Lynch's most recent trade in Longboard Pharmaceuticals Inc was a trade of 22,500 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Dec. 2, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 22,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 14,428 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 12,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 12,367 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 12,367 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 12,367 | 12,367 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 440,000 | 440,000 | - | - | Stock Option (right to buy) | |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.75 per share. | 10 May 2021 | 13,584 | 995,190 (3%) | 0% | 33.8 | 458,460 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.89 per share. | 10 May 2021 | 9,918 | 985,272 (3%) | 0% | 34.9 | 346,039 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.81 per share. | 10 May 2021 | 6,315 | 978,957 (3%) | 0% | 35.8 | 226,140 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.73 per share. | 10 May 2021 | 183 | 978,774 (3%) | 0% | 36.7 | 6,722 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.85 per share. | 22 Mar 2021 | 18,089 | 1,009,474 (3%) | 0% | 35.9 | 648,491 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.10 per share. | 22 Mar 2021 | 11,211 | 1,027,563 (3%) | 0% | 35.1 | 393,506 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.60 per share. | 22 Mar 2021 | 400 | 1,008,774 (3%) | 0% | 36.6 | 14,640 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.58 per share. | 22 Mar 2021 | 300 | 1,009,174 (3%) | 0% | 36.6 | 10,974 | Common Stock |
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 14,428 | 14,428 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Casey C. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 12,367 | 12,367 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.02 per share. | 01 Feb 2021 | 14,929 | 1,063,845 (3%) | 0% | 36.0 | 537,743 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 01 Feb 2021 | 8,032 | 1,039,374 (3%) | 0% | 45 | 361,440 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.56 per share. | 01 Feb 2021 | 7,460 | 1,083,528 (3%) | 0% | 36.6 | 272,738 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.75 per share. | 01 Feb 2021 | 5,071 | 1,058,774 (3%) | 0% | 36.7 | 186,359 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.60 per share. | 01 Feb 2021 | 4,686 | 1,094,088 (3%) | 0% | 34.6 | 162,136 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 37.68 per share. | 01 Feb 2021 | 4,283 | 1,079,245 (3%) | 0% | 37.7 | 161,383 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 41.91 per share. | 01 Feb 2021 | 3,100 | 1,050,818 (3%) | 0% | 41.9 | 129,921 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.59 per share. | 01 Feb 2021 | 3,100 | 1,090,988 (3%) | 0% | 35.6 | 110,329 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 40.84 per share. | 01 Feb 2021 | 2,000 | 1,053,918 (3%) | 0% | 40.8 | 81,680 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.22 per share. | 01 Feb 2021 | 1,900 | 1,047,406 (3%) | 0% | 44.2 | 84,018 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 38.64 per share. | 01 Feb 2021 | 1,600 | 1,056,774 (3%) | 0% | 38.6 | 61,824 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.10 per share. | 01 Feb 2021 | 1,512 | 1,049,306 (3%) | 0% | 43.1 | 65,167 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.82 per share. | 01 Feb 2021 | 856 | 1,055,918 (3%) | 0% | 39.8 | 34,086 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 45.73 per share. | 01 Feb 2021 | 600 | 1,038,774 (3%) | 0% | 45.7 | 27,438 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 37.39 per share. | 01 Feb 2021 | 400 | 1,058,374 (3%) | 0% | 37.4 | 14,956 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.23 per share. | 01 Feb 2021 | 371 | 1,078,774 (3%) | 0% | 39.2 | 14,554 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 38.28 per share. | 01 Feb 2021 | 100 | 1,079,145 (3%) | 0% | 38.3 | 3,828 | Common Stock |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Casey C. Lynch | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) |